Literature DB >> 6220000

Human leukemic cells resistant to 5-fluoro-2'-deoxyuridine contain a thymidylate synthetase with lower affinity for nucleotides.

A R Bapat, C Zarow, P V Danenberg.   

Abstract

A line of human lymphocytic leukemia cells (CCRF-CEM) has been obtained which is 140-fold resistant to the potent cell growth inhibitor 5-fluoro-2'-deoxyuridine (FdUrd). The cells were also 11-fold cross-resistant to 5-fluorouracil. In contrast to several previous studies involving FdUrd-resistant mouse cells, thymidylate synthetase levels were not substantially elevated in these FdUrd-resistant human leukemic cells. Thymidine kinase activity was also unchanged in the resistant cells, although the levels of 5-fluoro-2'-deoxyuridylate (FdUMP), the potent inhibitor of thymidylate synthetase, generated at equimolar doses of FdUrd were about 40% lower than in the sensitive cells. Studies of the kinetics of FdUMP binding to thymidylate synthetase isolated from the FdUrd-resistant cells disclosed a considerably higher dissociation constant (Kd = 1.0 X 10(-9) M) for the ternary covalent enzyme . FdUMP . 5,10-methylene tetrahydrofolate complex compared to the value obtained with enzyme from sensitive cells (Kd = 4.4 X 10(-11) M). The thymidylate synthetase from the FdUrd-resistant cells also showed 17-fold weaker binding of 2'-deoxyuridylate, even though the Km value for 2'-deoxyuridylate was 3-fold lower compared to the enzyme from FdUrd-sensitive cells. The turnover number of the altered enzyme was 1.8-fold higher than that for the normal enzyme but the rate constants for the release of FdUMP from the ternary complex, which is also an enzyme-catalyzed reaction, were identical for both enzymes. Electrophoresis of the radiolabeled ternary complexes on nondenaturing gels showed small but reproducible differences in migration rates. These results demonstrate that the mechanism of resistance to FdUrd in this cell line involves an alteration in the target enzyme, thymidylate synthetase, which causes it have a lower affinity for nucleotides.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6220000

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  In vitro enhancement of fluoropyrimidine-induced cytotoxicity by leucovorin in colorectal and gastric carcinoma cell lines but not in non-small-cell lung carcinoma cell lines.

Authors:  Y Sugimoto; Y Ohe; K Nishio; T Ohmori; Y Fujiwara; N Saijo
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Synthesis and biological evaluation of some phosphate triester derivatives of the anti-viral drug AraA.

Authors:  C McGuigan; S M Tollerfield; P A Riley
Journal:  Nucleic Acids Res       Date:  1989-08-11       Impact factor: 16.971

3.  Synthesis and biological evaluation of some phosphate triester derivatives of the anti-cancer drug araC.

Authors:  B C Jones; C McGuigan; P A Riley
Journal:  Nucleic Acids Res       Date:  1989-09-25       Impact factor: 16.971

4.  Synthesis and evaluation of some novel phosphate and phosphinate derivatives of araA. Studies on the mechanism of action of phosphate triesters.

Authors:  C McGuigan; J M Shackleton; S M Tollerfield; P A Riley
Journal:  Nucleic Acids Res       Date:  1989-12-25       Impact factor: 16.971

5.  Analysis of the thymidylate synthase gene structure in colorectal cancer patients and its possible relation with the 5-Fluorouracil drug response.

Authors:  A Calascibetta; Flavia Contino; S Feo; G Gulotta; M Cajozzo; A Antona; G Sanguedolce; R Sanguedolce
Journal:  J Nucleic Acids       Date:  2010-01-26

Review 6.  Implications of a Neuronal Receptor Family, Metabotropic Glutamate Receptors, in Cancer Development and Progression.

Authors:  Kevinn Eddy; Mohamad Naser Eddin; Anna Fateeva; Stefano Vito Boccadamo Pompili; Raj Shah; Saurav Doshi; Suzie Chen
Journal:  Cells       Date:  2022-09-13       Impact factor: 7.666

7.  Reduced activity of anabolizing enzymes in 5-fluorouracil-resistant human stomach cancer cells.

Authors:  M Inaba; J Mitsuhashi; H Sawada; N Miike; Y Naoe; A Daimon; K Koizumi; H Tsujimoto; M Fukushima
Journal:  Jpn J Cancer Res       Date:  1996-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.